further indications for calcium antagonists , still under evaluation , include congestive heart failure ( controversial ) , hypertrophic cardiomyopathy ( verapamil ) , primary pulmonary hypertension ( high doses required ) , raynaud 's phenomenon ( nifedipine and diltiazem effective ) , peripheral vascular disease ( proof not yet documented ) , cerebral insufficiency and subarachnoid hemorrhage ( nimodipine promising ) , migraine , exertional bronchospasm , renal disease , atherosclerosis ( experimental ) , and primary aldosteronism ( nifedipine inhibits aldosterone release ) .
C0038525
subarachnoid hemorrhage
C0028094
nimodipine